| 产品名称： | F98npEGFRvIII |
|---|---|
| 商品货号： | TS166733 |
| Organism： | Rattus norvegicus, rat |
| Tissue： | brain |
| Cell Type： | Glioblastoma |
| Product Format： | frozen |
| Morphology： | glial |
| Culture Properties： | adherent |
| Biosafety Level： | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | undifferentiated malignant glioma |
| Age： | fetus, 20 days gestation |
| Applications： | This cell line has been used for in vivo studies of molecular targeting of EGFRvIII in syngeneic Fischer rats. Ref   Yang W, et al. Development of a Syngeneic Rat Brain Tumor Model Expressing EGFRvIII and Its Use for Molecular Taregeting Studies with Monoclonal Antibody L8A4. Clin. Cancer Res. 11(1): 341-350, 2005. PubMed: 15671565 |
| Storage Conditions： | liquid nitrogen vapor phase |
| Derivation： | Epidermal Growth Factor Receptor (EGFR)-expressing F98 glioma cells (F98EGFR) were produced by transfecting F98 (ATCC CRL-2397) with an expression vector containing human EGFRvIII cDNA. |
| Receptor Expression： | Epidermal Growth Factor Receptor vIII (EGFRvIII), expressed (verified at ATCC) |
| Tumorigenic： | YES |
| Effects： | tumorigenic in syngeneic Fischer rats |
| Comments： | EGFRvIII is a truncated extracellular mutant of the EGF receptor commonly found in glioblastomas that confers enhanced tumorigenic behavior. The receptors are very weakly phosphorylated.xa0 |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated Dulbeccos Modified Eagles Medium, Catalog No. 30-2002.
To make the complete growth medium, add the following components to the base medium:
|
| Subculturing： | Volumes used in this protocol are for 75 cm2 flasks; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.
Note: If cells are cultured continuously, add 0.6 mg/mL G-418 to the complete growth medium for a passage about once a month.
Subcultivation ratio: A subcultivation ratio of 1:6 to 1:10 is recommended. Medium renewal: Every 2 to 3 days. |
| Cryopreservation： | Freeze medium: complete growth medium, 95%; DMSO, 5% liquid nitrogen vapor phase |
| Culture Conditions： | Temperature:xa037°C
Atmosphere:xa0air, 95%; carbon dioxide (CO2), 5% |
| Population Doubling Time： | about 17 hours |
| Name of Depositor： | RF Barth |
| Year of Origin： | April 2001 |
| References： | Yang W, et al. Development of a Syngeneic Rat Brain Tumor Model Expressing EGFRvIII and Its Use for Molecular Taregeting Studies with Monoclonal Antibody L8A4. Clin. Cancer Res. 11(1): 341-350, 2005. PubMed: 15671565 Yang W, et al. Convection enhanced delivery of boronated epidermal growth factor for molecular targeting of EGFR positive gliomas. Cancer Res. 62: 6552-6558, 2002. PubMed: 12438250 Barth RF, et al. Molecular targeting of the epidermal growth factor receptor for neutron capture therapy of gliomas. Cancer Res. 62(11): 3159-3166, 2002. PubMed: 12036929 Wu G, et al. Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates. Mol. Cancer Ther. 5(1): 52-59, 2006. PubMed: 16432162. Wu G, et al. Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab. Clin. Cancer Res. 13(4): 1260-1268, 2007. PubMed: 17317838 Yang W, et al. Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies. Clin. Cancer Res. 14(3): 883-891, 2008. PubMed: 18245552 |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | F98npEGFRvIII |
|---|---|
| 商品货号： | TS166733 |
| Organism： | Rattus norvegicus, rat |
| Tissue： | brain |
| Cell Type： | Glioblastoma |
| Product Format： | frozen |
| Morphology： | glial |
| Culture Properties： | adherent |
| Biosafety Level： | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | undifferentiated malignant glioma |
| Age： | fetus, 20 days gestation |
| Applications： | This cell line has been used for in vivo studies of molecular targeting of EGFRvIII in syngeneic Fischer rats. Ref Yang W, et al. Development of a Syngeneic Rat Brain Tumor Model Expressing EGFRvIII and Its Use for Molecular Taregeting Studies with Monoclonal Antibody L8A4. Clin. Cancer Res. 11(1): 341-350, 2005. PubMed: 15671565 |
| Storage Conditions： | liquid nitrogen vapor phase |
| Derivation： | Epidermal Growth Factor Receptor (EGFR)-expressing F98 glioma cells (F98EGFR) were produced by transfecting F98 (ATCC CRL-2397) with an expression vector containing human EGFRvIII cDNA. |
| Receptor Expression： | Epidermal Growth Factor Receptor vIII (EGFRvIII), expressed (verified at ATCC) |
| Tumorigenic： | YES |
| Effects： | tumorigenic in syngeneic Fischer rats |
| Comments： | EGFRvIII is a truncated extracellular mutant of the EGF receptor commonly found in glioblastomas that confers enhanced tumorigenic behavior. The receptors are very weakly phosphorylated.xa0 |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated Dulbeccos Modified Eagles Medium, Catalog No. 30-2002.
To make the complete growth medium, add the following components to the base medium:
|
| Subculturing： | Volumes used in this protocol are for 75 cm2 flasks; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.
Note: If cells are cultured continuously, add 0.6 mg/mL G-418 to the complete growth medium for a passage about once a month.
Subcultivation ratio: A subcultivation ratio of 1:6 to 1:10 is recommended. Medium renewal: Every 2 to 3 days. |
| Cryopreservation： | Freeze medium: complete growth medium, 95%; DMSO, 5% liquid nitrogen vapor phase |
| Culture Conditions： | Temperature:xa037°C
Atmosphere:xa0air, 95%; carbon dioxide (CO2), 5% |
| Population Doubling Time： | about 17 hours |
| Name of Depositor： | RF Barth |
| Year of Origin： | April 2001 |
| References： | Yang W, et al. Development of a Syngeneic Rat Brain Tumor Model Expressing EGFRvIII and Its Use for Molecular Taregeting Studies with Monoclonal Antibody L8A4. Clin. Cancer Res. 11(1): 341-350, 2005. PubMed: 15671565 Yang W, et al. Convection enhanced delivery of boronated epidermal growth factor for molecular targeting of EGFR positive gliomas. Cancer Res. 62: 6552-6558, 2002. PubMed: 12438250 Barth RF, et al. Molecular targeting of the epidermal growth factor receptor for neutron capture therapy of gliomas. Cancer Res. 62(11): 3159-3166, 2002. PubMed: 12036929 Wu G, et al. Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates. Mol. Cancer Ther. 5(1): 52-59, 2006. PubMed: 16432162. Wu G, et al. Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab. Clin. Cancer Res. 13(4): 1260-1268, 2007. PubMed: 17317838 Yang W, et al. Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies. Clin. Cancer Res. 14(3): 883-891, 2008. PubMed: 18245552 |
